Complex generics are becoming the more widely manufactured pharmaceutical drug, giving stakeholders opportunities and challenges to grow. A 4Ps analysis (Product, Price, Place, and Promotion) study was conducted quantitatively to know the market share of complex generics in the United States and India. SWOC (Strength, Weakness, Opportunities, and Challenges) analysis is a method of analyzing internal and external strengths to develop strategic planning and management techniques to achieve a good marketing position in case of complex generics. The increased demand for complex generics, driven by their affordability compared to name-brand equivalents is highlighted in the strength section. The regulatory obstacles and complexity of the manufacturing process present significant barriers in the weaknesses segment. The opportunities section looks at ways to grow the industry, such as developing strategic relationships with new technologies like continuous manufacturing procedures and model informed formulation development. Lastly, the challenges faced by complex generic companies. Maintaining bio-equivalency standards and ensuring quality control are major issues affecting customer confidence and industry penetration. This article highlights the dynamic nature of the complex generics market and provides stakeholders with helpful information for making strategic decisions to effectively navigate the complex nature of this particular market sector and achieve long-term growth.